Blood Reviews
Volume 21, Issue 4 , Pages 173-182 , July 2007

Farnesyltransferase inihibitors in hematologic malignancies

References 

  1. End DW, Mevellec L, Angibaud P. Farnesyl protein transferase inhibitors: molecular mechanisms and progress in the clinic. Curr Top Med Chem. In press.
  2. End DW. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs. 1999;17:241–258
  3. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631–3652
  4. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;366:643–654
  5. Khosravi-Far R, Cox AD, Kato K, Der CJ. Protein prenylation: key to ras function and cancer intervention?. Cell Growth Differ. 1992;3:461–469
  6. Rodenhuis S. ras and human tumors. Semin Cancer Biol. 1992;3:241–247
  7. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  8. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood. 2000;96:1655–1669
  9. Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003;102:3880–3889
  10. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376:599–602
  11. Klippel A, Escobedo MA, Wachowicz MS, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol. 1998;18:5699–5711
  12. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131–137
  13. Cox AD, Der CJ. Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol. 2002;2:388–393
  14. Feldman EJ. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep. 2005;4:186–190
  15. Ganguly AK, Doll RJ, Girijavallabhan VM. Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336. Curr Med Chem. 2001;8:1419–1436
  16. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol. 2001;38:16–23
  17. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by a gain of geranylgeranylated RhoB. Mol Cell Biol. 1999;19:1831–1840
  18. Ashar HR, James L, Gray K, et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2) –>M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res. 2001;262:17–27
  19. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem. 2001;276:16161–16167
  20. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem. 1997;272:15591–15594
  21. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18:927–941
  22. Korycka A, Smolewski P, Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol. 2004;73:418–426
  23. Mackenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G. Mutant N-ras induces myeloproliferatives disorders and apoptosis in bone marrow repopulated mice. Blood. 1999;93:2043–2056
  24. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361–3369
  25. Harousseau JL, Reiffers J, Lowenberg B, et al. Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter phase 2 study. Blood. 2003;102(Pt1):176a;Abstract 614
  26. Lancet JE, Gotlib J, Gojo I, et al. Tipifarnib (ZARNESTRATM) in previously untreated poor-risk AML of the elderly: updated results of a multicenter phase 2 trial. Blood. 2004;104(pt1):249a;Abstract 874
  27. Raponi M, Lowenberg B, Lancet JE, et al. Identification of molecular predictors of response to ZARNESTRATM (tipifarnib, R115777) in relapsed and refractory acute myeloid leukemia. Blood. 2004;104:246a;Abstract 861
  28. Zimmerman TM, Harlin H, Odenike OM, et al. Dose ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004;22:4764–4770
  29. Karp JE, Gojo I, Greer J, et al. Tipifarnib (ZARNESTRA, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial. Blood. 2005;106:780a;Abstract 2783
  30. List AF, DeAngelo D, O’Brien S, et al. Phase I study of continuous oral administration of lonafarnib (SarasarTM) in patients with advanced hematologic malignancies. Blood. 2002;100:789a;Abstract 3120
  31. Cortes J, Holyoake TL, Silver RT, et al. Continuous oral lonafarnib (SarasarTM) for the treatment of patients with advanced hematologic malignancies: a phase II study. Blood. 2002;100:793a;Abstract 3132
  32. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003;102:4527–4534
  33. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004;22:1287–1292
  34. Kurzrock R, Fenaux P, Raza A, et al. High-risk myelodysplastic syndrome (MDS): first results of international phase 2 study with oral farnesyltransferase inhibitor R115777 ZARNESTRATM). Blood. 2004;104(pt 1):23a;Abstract 68
  35. Kurzrock R, Verstovsek S, Wright JJ, et al. Phase I study using alternate week administration of the farnesyl transferase inhibitor R115777 (Zarnestra) in patients with myelodysplastic syndrome. Blood. 2004;104(Pt 1):402a;Abstract 1436
  36. Feldman EJ, Cortes J, Holyoake TL, et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome. Blood. 2003;102:421a;Abstract 1531
  37. Peters DG, Hoower RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 agains BCR/ABL_induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404–1412
  38. Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001;97:1399–1403
  39. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068–1071
  40. Nakajima A, Tauchi T, Ohyashiki K. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia. 2001;15:989–990
  41. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid and other hematologic malignancies. Blood. 2003;101:1692–1697
  42. Gotlib J, Mauro M, O’Dwyer ME, et al. Tipifarnib (ZARNESTRA) and Imatinib (GLEEVEC) combination therapy in patients with advanced chronic myelogenous leukemia (CML): preliminary results of a phase I study. Blood. 2003;102:909a;Abstract 3384
  43. Borthakur G, Kantarjian H, Daley G, et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006;106:346–352
  44. Cortes J, Garcia-Manero G, O’Brien S, et al. A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy. Blood. 2004;104(Pt 1):176;Abstract 1011
  45. Le Gouill S, Pellat-Deceunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia. 2002;16:1664–1667
  46. Ochiai N, Uchida R, Fuchida S, et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood. 2003;102:3349–3353
  47. Bolick SC, Landowski TH, Boulware D, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 2003;17:451–457
  48. Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther. 2004;3:179–186
  49. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004;103:3271–3277
  50. David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood. 2005;106:4322–4329
  51. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–1265
  52. Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia. 2003;17:849–855

PII: S0268-960X(06)00075-0

doi: 10.1016/j.blre.2006.12.001

Blood Reviews
Volume 21, Issue 4 , Pages 173-182 , July 2007

Article Tools

* Image Usage & Resolution